Publications by authors named "Fatemeh Sokhanvari"

This study aimed to investigate the effects of topical liposomal clarithromycin in combination with (Glucantime) on cutaneous leishmaniasis (CL) lesions. This pilot, randomized, double-blinded clinical trial was conducted on patients with CL lesions. Patients were randomly assigned to two groups: the first group received liposomal clarithromycin in combination with Glucantime for 28 days, while the second group received Glucantime and a placebo.

View Article and Find Full Text PDF

Background: Cutaneous manifestations of coronavirus disease 2019 (COVID-19) range from mild skin rashes to severe vasculitis. In the current study, we evaluated the demographic characteristics of the patients with cutaneous vasculitis following COVID-19 infection.

Materials And Methods: In the current study, we evaluated 799 hospitalised patients with COVID-19 infection for development of cutaneous vasculitis.

View Article and Find Full Text PDF

The treatment of Cutaneous Leishmaniasis (CL) is complex, and the search for safer, more efficient, and cost-effective treatments is ongoing. This study aimed to evaluate the efficacy of the combination of liposomal and oral azithromycin as the first clinical study against CL. This assessor-blind, randomized clinical trial was conducted in out-patients Leishmaniasis clinic of Skin Diseases and Leishmaniasis.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to analyze the spatial distribution of cutaneous leishmaniasis (CL) incidence in Isfahan, Iran, using Geographic Information Systems (GIS) over a five-year period (2014-2018).
  • A higher incidence was found in males aged 18-64, with a peak in autumn (58.6%), while the overall trend showed fluctuations, notably an increase in 2018 except in two counties.
  • Hot spots for CL cases were identified primarily in central Isfahan, with Varzaneh being the most affected area throughout all years of the study.
View Article and Find Full Text PDF
Article Synopsis
  • * Imatinib, an anticancer drug known for inhibiting protein kinases, was tested for its effectiveness against CL due to the crucial role of these enzymes in the disease.
  • * In a study using Balb/c mice, imatinib at a dose of 50 mg/kg showed significant improvement in treating CL ulcers compared to a negative control group, indicating its potential as a treatment option.
View Article and Find Full Text PDF

Background: Leishmaniasis is an infectious disease caused by an intracellular parasite of and is transmitted through the female sandflies bite and may lead to severe skin lesions. Although drugs such as antimony compounds are available, their side effects such as toxicity, low efficacy, and emergence of resistance have raised the importance of effective replacement. Imatinib, as an inhibitor of tyrosine kinase (TK) of , stops abnormal function of TK such as Bcr-Abl through assembling into transmembrane pores in a sterol-dependent manner.

View Article and Find Full Text PDF

Objectives: Leishmaniasis is one of the main health problems in developing countries, caused by intracellular protozoan parasites of the Leishmania genus. Although research has been successful in discovering vaccines and anti-parasitic drugs like antimony compounds, their side effects like high toxicity, prolonged regeneration, etc., have raised the replacement importance of natural products with antioxidant and antibacterial properties.

View Article and Find Full Text PDF